Michael R Eber, Rebecca Costa, Stephanie Argetsinger, Mahnum Shahzad, Fang Zhang, J Frank Wharam, Dennis Ross-Degnan, Anita K Wagner
{"title":"Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment.","authors":"Michael R Eber, Rebecca Costa, Stephanie Argetsinger, Mahnum Shahzad, Fang Zhang, J Frank Wharam, Dennis Ross-Degnan, Anita K Wagner","doi":"10.37765/ajmc.2026.90025","DOIUrl":"https://doi.org/10.37765/ajmc.2026.90025","url":null,"abstract":"<p><strong>Objectives: </strong>Out-of-pocket (OOP) spending obligations associated with high-deductible health plans (HDHPs) may reduce health care utilization, but evidence on how enrollment in HDHPs affects use of oral targeted anticancer medications (OTAMs) is limited. We used difference-in-differences regression analyses to examine the associations among employer-mandated enrollment in an HDHP, OOP spending, and use of OTAMs in a commercially insured population between 2007 and 2021. Among users of OTAMs, we found that HDHP enrollment may have increased OOP spending but was not associated with reductions in the use of these anticancer agents over a 1-year follow-up period. Research should continue to examine the links among patient cost sharing, cancer care utilization, and spending trade-offs, particularly for low-income patients with cancer.</p>","PeriodicalId":50808,"journal":{"name":"American Journal of Managed Care","volume":"32 10","pages":"545-547"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"External Validation and Adaptation of the Cambridge Multimorbidity Score Using German Claims Data.","authors":"Kateryna Karimova, Iulia Dahmer, Catriona Friedmacher, Anastasiya Glushan, Justyna Weronika Wuenstel","doi":"10.37765/ajmc.2026.90033","DOIUrl":"10.37765/ajmc.2026.90033","url":null,"abstract":"<p><strong>Objectives: </strong>The Cambridge Multimorbidity Score (CMMS) is a well-regarded indicator for predicting primary care visits, hospital admissions, and mortality. However, it is not compatible with the International Classification of Diseases, Tenth Revision ( ICD-10 ). This study aimed to translate the CMMS to ICD-10 , assess its performance, and evaluate its usefulness in primary care using German claims data. We then compared 3 measures-our translated ICD-10 version of the CMMS, the Charlson Comorbidity Index, and a version recalibrated to our study population to predict hospitalizations, mortality, and ambulatory care-sensitive conditions (ACSCs).</p><p><strong>Study design: </strong>Retrospective observational cohort study (2011-2022). Two data sets were used: a whole adult insured population (3,809,220) with 1-year follow-up, and a subset of 217,964 patients with diabetes mellitus with 11-year follow-up.</p><p><strong>Methods: </strong>The predictive performance for binary outcomes-hospitalization, mortality, and ACSCs-was assessed through external validation of the CMMS, using the original Payne et al score. In addition, we re-estimated the weights for the existing conditions from the original CMMS to reflect their prevalence in the German population.</p><p><strong>Results: </strong>The CMMS outperformed the CCI by 2.7 percentage points for ACSCs, 3.6 percentage points for mortality, and 4.0 percentage points for hospitalization within 1 year. Over 11 years, Payne's CMMS showed the highest discrimination (C-index 0.663 vs 0.651 for CCI). The CMMS with population-derived weights performed similarly to the original CMMS in all analyses.</p><p><strong>Conclusions: </strong>The CMMS demonstrated improved predictive accuracy over the CCI for mortality, hospitalizations, and ACSCs, supporting its use for risk stratification and health care planning in German primary care and comparable populations.</p>","PeriodicalId":50808,"journal":{"name":"American Journal of Managed Care","volume":"32 10","pages":"e372-e378"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Simulating the Impact of the Transforming Episode Accountability Model.","authors":"Zehui Zhou, Jason D Buxbaum, Andrew M Ryan","doi":"10.37765/ajmc.2026.90027","DOIUrl":"10.37765/ajmc.2026.90027","url":null,"abstract":"<p><strong>Objectives: </strong>To simulate the financial impact of Medicare's Transforming Episode Accountability Model (TEAM) on CMS and assess variation in incentive payments across hospital types and geographic regions from 2026 to 2030.</p><p><strong>Study design: </strong>We developed a simulation model to project hospital-level incentive payments and CMS savings under alternative TEAM design scenarios. The model incorporated hospital and patient characteristics, clinical episode categories, and target prices to estimate reconciliation payments, accounting for TEAM's mandatory participation and episode structure. Analyses included projections at the national level and by hospital type and state.</p><p><strong>Methods: </strong>We applied random forest models using data from Model Year 4 (2021) of the Bundled Payments for Care Improvement Advanced (BPCI-A) program obtained through a Freedom of Information Act request. We identified 710 acute care hospitals required to participate in TEAM based on the CMS participant list after linking the data to BPCI-A target price and Inpatient Prospective Payment System impact files (2018-2021).</p><p><strong>Results: </strong>Assuming a $500 per-episode reduction in spending, TEAM is projected to yield $2.6 million in savings in 2026 and $46.6 million in 2030. In 2030, safety-net hospitals are projected to receive the highest average reconciliation payments ($962 per episode), followed by rural ($620) and urban non-safety-net hospitals ($77). Nebraska is projected to receive the highest average payments, whereas Oregon may face the largest penalties.</p><p><strong>Conclusions: </strong>TEAM is projected to produce modest Medicare savings with substantial variation in hospital payments, highlighting the importance of balancing incentives across hospital types and regions.</p>","PeriodicalId":50808,"journal":{"name":"American Journal of Managed Care","volume":"32 10","pages":"557-562"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"LDCT Screening Cost-Effectiveness for Familial Lung Cancer Risk in Taiwan.","authors":"Feng-Chi Hsieh, Chao-Hong Liu, Hon-Yi Shi","doi":"10.37765/ajmc.2026.90032","DOIUrl":"https://doi.org/10.37765/ajmc.2026.90032","url":null,"abstract":"<p><strong>Objectives: </strong>Most economic evaluations of low-dose CT (LDCT) screening focus on heavy smokers, with limited evidence for individuals with a family history of lung cancer (LCFH). This study evaluated the cost-effectiveness of LDCT screening for individuals with LCFH using Taiwan epidemiologic data and cost data derived from the Taiwan National Health Insurance program.</p><p><strong>Study design: </strong>A Markov model simulation evaluated the cost-effectiveness of LDCT screening vs nonscreening using 10,000 iterations in the probabilistic sensitivity analysis, a 1-year cycle, a 20-year time horizon, and a 3% annual discount rate.</p><p><strong>Methods: </strong>The analysis adopted the perspective of the Taiwan health care payer and assumed annual LDCT screening with full adherence. The willingness-to-pay (WTP) threshold was set at $32,440, corresponding to Taiwan's 2024 gross domestic product per capita. We used incremental costs and quality-adjusted life years (QALYs) to calculate the incremental cost-utility ratio (ICUR). Deterministic and probabilistic sensitivity analyses were conducted to evaluate parameter uncertainty.</p><p><strong>Results: </strong>At the specified WTP threshold, LDCT screening yielded an ICUR of $23,786/QALYs, which was below the prespecified WTP threshold. In the simulated cohort, 158,375 LDCT examinations resulted in 609 lung cancer diagnoses over 20 years. Probabilistic sensitivity analysis demonstrated a 61.22% probability of cost-effectiveness. Results were most sensitive to lung cancer incidence in the nonscreening cohort, LDCT positivity rate, and positive predictive value.</p><p><strong>Conclusions: </strong>LDCT screening for individuals with LCFH was cost-effective at the selected threshold under modeled assumptions. Targeted implementation in high-risk populations may enhance value-based resource allocation; however, real-world adherence, evolving treatment costs, and program scalability should be considered in coverage and reimbursement decisions.</p>","PeriodicalId":50808,"journal":{"name":"American Journal of Managed Care","volume":"32 10","pages":"e364-e371"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christine D Jones, Marguerite Daus, Emily A Gadbois, Jennifer Bunker, Jamie M Smith, Kali S Thomas
{"title":"Perspectives on Health-Related Social Needs for Medicare Advantage Beneficiaries.","authors":"Christine D Jones, Marguerite Daus, Emily A Gadbois, Jennifer Bunker, Jamie M Smith, Kali S Thomas","doi":"10.37765/ajmc.2026.90028","DOIUrl":"10.37765/ajmc.2026.90028","url":null,"abstract":"<p><strong>Objectives: </strong>We sought to characterize current approaches to address health-related social needs that arise for Medicare Advantage (MA) members in the context of postacute home health care.</p><p><strong>Study design: </strong>Qualitative study.</p><p><strong>Methods: </strong>From March 2023 to June 2024, we interviewed 18 representatives from 14 MA organizations representing more than 62.4% of the MA market and 5 representatives from 5 postacute care management companies (CMCs) about approaches to health-related social needs. Interviews were audio recorded, transcribed, and analyzed using content analysis to identify themes.</p><p><strong>Results: </strong>Three themes were identified related to health-related social needs: motivations, approaches, and lessons learned and aspirations. Motivations included fulfilling organizational missions, meeting individual or community member needs, and differentiating from other MA plans to improve enrollment and retention. Approaches varied and leveraged internal teams, CMCs, and/or community partnerships to screen and connect members to resources. Lessons learned focused on rightsizing staffing while managing program costs. Aspirations centered on expanding how MA organizations and Medicare might broaden allowable supplemental benefit coverage for health-related social needs.</p><p><strong>Conclusions: </strong>The motivations and approaches that MA organizations and CMCs use to address members' social needs vary widely. Notable innovative approaches included partnerships with local community organizations with the intent to differentiate and grow plans as well as an emerging role for CMCs in identifying and addressing social needs during postacute care transitions.</p>","PeriodicalId":50808,"journal":{"name":"American Journal of Managed Care","volume":"32 10","pages":"566-574"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah E Vordenberg, Ellah Bliler, Daniel Rivera Rivera, Garth W Strohbehn, Eli W Carter, Dina H Griauzde, A Mark Fendrick
{"title":"Making Obesity Care Affordable: Patient Views on Deprescribing GLP-1 RAs.","authors":"Sarah E Vordenberg, Ellah Bliler, Daniel Rivera Rivera, Garth W Strohbehn, Eli W Carter, Dina H Griauzde, A Mark Fendrick","doi":"10.37765/ajmc.2026.89946","DOIUrl":"https://doi.org/10.37765/ajmc.2026.89946","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the acceptability of deprescribing injectable incretin mimetics for weight management (IMWMs) among self-identified individuals with obesity in the US.</p><p><strong>Study design: </strong>An online survey was conducted in November 2024.</p><p><strong>Methods: </strong>Respondents (N = 704) watched 2 videos summarizing IMWM risks and benefits. The primary quantitative outcome was agreement with insurers paying for IMWMs during active weight loss and encouraging lower-cost alternatives during maintenance. Descriptive statistics and χ 2 tests were conducted to analyze the data. Qualitative analysis centered on inductive content analysis of respondents' responses to a free-text question about concerns with transitioning from IMWMs to an alternative weight management strategy.</p><p><strong>Results: </strong>Most respondents agreed with encouraging the strategy (n = 582; 82.7%) and would support their friends or family members switching to low-cost alternatives to expand access to IMWMs (89.8%). Broad coverage of effective, lower-cost treatment options was identified as a critical component of such programs. Common response themes included attitudes toward weight loss medications (44.4%), such as adverse events (26.9%) and the fear of worsening health if the IMWM is stopped (30.2%), primarily related to gaining weight back or maintaining weight loss (25.2%).</p><p><strong>Conclusions: </strong>IMWM deprescribing programs are, in principle, acceptable to individuals with obesity. Additional research is needed to determine the feasibility and real-world outcomes of adults with obesity switching to lower-cost alternatives during weight maintenance.</p>","PeriodicalId":50808,"journal":{"name":"American Journal of Managed Care","volume":"32 10","pages":"576-581"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Taha Erdinç Sariçimen, Murat Özdede, Mine Durusu Tanriover, Aygin Bayraktar-Ekincioğlu
{"title":"Closing the Gap in Thromboprophylaxis: A Multidisciplinary Quality Improvement Approach Among Medical Inpatients.","authors":"Taha Erdinç Sariçimen, Murat Özdede, Mine Durusu Tanriover, Aygin Bayraktar-Ekincioğlu","doi":"10.37765/ajmc.2026.90031","DOIUrl":"https://doi.org/10.37765/ajmc.2026.90031","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the impact of a multidisciplinary quality improvement (QI) framework on guideline-directed venous thromboembolism (VTE) prophylaxis adherence among hospitalized patients.</p><p><strong>Study design: </strong>A prospective, pre-post interventional study conducted in internal medicine wards with historically low baseline prophylaxis rates.</p><p><strong>Methods: </strong>Following a retrospective baseline assessment, a multicomponent QI initiative was executed across 2 Plan-Do-Study-Act cycles in adult internal medicine wards at a university hospital between September and November 2022. Interventions included the following: (1) physician education on the Padua Prediction Score and International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score; (2) implementation of an electronic health record clinical decision-support tool prompting VTE risk assessments; and (3) integration of clinical pharmacists into daily multidisciplinary rounds to provide active audit and feedback.</p><p><strong>Results: </strong>At baseline, 62.1% of high-risk patients received guideline-recommended VTE prophylaxis. Post intervention, this rate increased to 79.1% in the first cycle and 82.1% in the second cycle ( P = .006). Among clinical pharmacists' 27 recommendations, 70.4% were accepted and implemented. The multidimensional strategy demonstrated sustained improvements in guideline adherence with minimal adverse events.</p><p><strong>Conclusions: </strong>Implementing a multidisciplinary QI framework significantly enhanced guideline-directed VTE prophylaxis use among hospitalized patients. This collaborative approach underscores the value of electronic decision support, clinical audit-feedback loops, and pharmacist-physician integration in driving patient safety. Ultimately, this system-level strategy provides a scalable model for improving preventive care protocols across diverse hospital settings.</p>","PeriodicalId":50808,"journal":{"name":"American Journal of Managed Care","volume":"32 10","pages":"e355-e363"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ashwanth Kumar, Jacob T Kannarkat, Joseph T Kannarkat
{"title":"Containing Chronic Disease Costs With the Ambulatory Specialty Model.","authors":"Ashwanth Kumar, Jacob T Kannarkat, Joseph T Kannarkat","doi":"10.37765/ajmc.2026.90029","DOIUrl":"https://doi.org/10.37765/ajmc.2026.90029","url":null,"abstract":"<p><p>On July 14, 2025, CMS proposed and requested comment on establishing the Ambulatory Specialty Model, a mandatory payment model for specialists treating heart failure (eg, cardiologists) and low back pain (eg, anesthesiologists, neurosurgeons, physical medicine and rehabilitation). Comments were due on September 12, 2025, with notable responses from various stakeholders (eg, surgery centers, cardiologists, consulting firms). The model is notable for several reasons, including strict implementation of a 2-sided risk model, inclusion of specialists typically insulated from involvement in alternative payment models, and a new approach to performance measurement. In this article, we aim to inform clinicians-specialists in particular-about key aspects of the model, as they are likely to be unaware of its impending mandatory nature, and to provide recommendations for how the model can be improved to achieve its intended goal while mitigating unintended clinical and economic consequences.</p>","PeriodicalId":50808,"journal":{"name":"American Journal of Managed Care","volume":"32 10","pages":"e349-e351"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Olivia S Jung, Ilana Graetz, Shreya Huilgol, Denise A Moultrie, Christopher M Masi
{"title":"Learning Health System Characteristics and Burnout in Primary Care.","authors":"Olivia S Jung, Ilana Graetz, Shreya Huilgol, Denise A Moultrie, Christopher M Masi","doi":"10.37765/ajmc.2026.90030","DOIUrl":"https://doi.org/10.37765/ajmc.2026.90030","url":null,"abstract":"<p><strong>Objectives: </strong>Although learning-oriented work environments may reduce burnout, practice transformation and technology adoption associated with learning health systems (LHS) have also been linked to increased burnout. Understanding how LHS characteristics relate to burnout is essential to guide implementation. We examined whether primary care clinicians' and staff members' perceptions of learning within their clinics were associated with burnout.</p><p><strong>Study design: </strong>We conducted cross-sectional surveys in September 2022 and November 2023 among clinicians and staff in Emory Healthcare primary care clinics.</p><p><strong>Methods: </strong>Burnout was assessed in 2023 using a validated single-item measure rated on a 7-point Likert scale. Perceptions of learning were measured in 2022 using 7 domains from the short-form Learning Organization Survey: supportive learning environment, leadership that reinforces learning, experimentation, time for reflection, knowledge acquisition, training, and performance monitoring. Linear regression models examined associations between learning domains and burnout, adjusting for role, organizational tenure, and exposure to a new electronic health record implementation and an innovation contest. Robust standard errors were used.</p><p><strong>Results: </strong>The analytic sample included 139 employees who completed both surveys. In 2023, 56% reported burnout (mean [SD], 4.35 [1.81]). Higher perceptions of learning were significantly associated with lower burnout across multiple learning domains, including supportive learning environment, leadership that reinforces learning, experimentation, time for reflection, and knowledge acquisition.</p><p><strong>Conclusions: </strong>These findings suggest that LHS characteristics may support clinician and staff well-being by addressing organizational contributors to burnout. Embedding learning-oriented leadership, reflection time, and experimentation into care delivery may help align improvements in patient care with workforce sustainability.</p>","PeriodicalId":50808,"journal":{"name":"American Journal of Managed Care","volume":"32 10","pages":"e353-e354"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M Christopher Roebuck, Paul Fronstin, Troyen A Brennan
{"title":"Divergent Cost Trends for 3 Advanced Cancers, 2013 vs 2022: A Commercial Claims Analysis.","authors":"M Christopher Roebuck, Paul Fronstin, Troyen A Brennan","doi":"10.37765/ajmc.2026.90026","DOIUrl":"10.37765/ajmc.2026.90026","url":null,"abstract":"<p><strong>Objectives: </strong>Cancer is cited by most employers as the leading condition driving rising health care benefit costs. This study examined the components of and trends in health care costs for patients with 3 advanced cancers, focusing on employer-sponsored insurance. We evaluated how the costs of various cancer care modalities changed between 2013 and 2022 during a period marked by the introduction of novel therapies alongside generic and biosimilar competition.</p><p><strong>Study design: </strong>Retrospective observational claims analysis.</p><p><strong>Methods: </strong>Using MarketScan Commercial Claims and Encounters data, we compared 12-month health services costs for patients newly diagnosed with metastatic colorectal cancer, metastatic non-small cell lung cancer (NSCLC), or multiple myeloma in 2013 vs 2022.</p><p><strong>Results: </strong>Metastatic colorectal cancer costs decreased 15% (from $239,003 in 2013 to $203,499 in 2022), coinciding with generic competition for chemotherapy and biosimilar entry for supportive medications. Conversely, costs for metastatic NSCLC increased by 25% (from $220,662 to $276,883), and costs for multiple myeloma increased by 51% (from $216,337 to $327,495), both due to immunotherapy. Censoring rates were lower in 2022 for all 3 cancers, significantly so for metastatic NSCLC.</p><p><strong>Conclusions: </strong>Cancer costs for employers are not uniformly increasing, but instead, shifting based on market competition and therapeutic innovation. Where costs are rising, they are driven by novel therapies that offer a potential value trade-off, coinciding with survival improvements reported in the literature.</p>","PeriodicalId":50808,"journal":{"name":"American Journal of Managed Care","volume":"32 10","pages":"548-555"},"PeriodicalIF":2.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}